Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5071745
Max Phase: Preclinical
Molecular Formula: C32H35N7O3
Molecular Weight: 565.68
Molecule Type: Unknown
Associated Items:
ID: ALA5071745
Max Phase: Preclinical
Molecular Formula: C32H35N7O3
Molecular Weight: 565.68
Molecule Type: Unknown
Associated Items:
Canonical SMILES: N=C(N)NCCC[C@@H](NC(=O)C=C(c1ccccc1)c1ccccc1)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(N)=O
Standard InChI: InChI=1S/C32H35N7O3/c33-30(41)28(18-23-20-37-26-15-8-7-14-24(23)26)39-31(42)27(16-9-17-36-32(34)35)38-29(40)19-25(21-10-3-1-4-11-21)22-12-5-2-6-13-22/h1-8,10-15,19-20,27-28,37H,9,16-18H2,(H2,33,41)(H,38,40)(H,39,42)(H4,34,35,36)/t27-,28-/m1/s1
Standard InChI Key: AFCJWUBFGQMXMR-VSGBNLITSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 565.68 | Molecular Weight (Monoisotopic): 565.2801 | AlogP: 2.56 | #Rotatable Bonds: 13 |
Polar Surface Area: 178.98 | Molecular Species: BASE | HBA: 4 | HBD: 7 |
#RO5 Violations: 2 | HBA (Lipinski): 10 | HBD (Lipinski): 9 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 12.45 | CX Basic pKa: 11.83 | CX LogP: 2.22 | CX LogD: 0.12 |
Aromatic Rings: 4 | Heavy Atoms: 42 | QED Weighted: 0.06 | Np Likeness Score: 0.03 |
1. Quillet R, Schneider S, Utard V, Drieu la Rochelle A, Elhabazi K, Henningsen JB, Gizzi P, Schmitt M, Kugler V, Simonneaux V, Ilien B, Simonin F, Bihel F.. (2021) Identification of an N-acylated-DArg-Leu-NH2 Dipeptide as a Highly Selective Neuropeptide FF1 Receptor Antagonist That Potently Prevents Opioid-Induced Hyperalgesia., 64 (11.0): [PMID:34008968] [10.1021/acs.jmedchem.1c00256] |
Source(1):